Cheryl Gault, Chief Executive Officer at Rapport Therapeutics, Inc. (RAPP), sold 4,522 shares at $32.03 ($143K) on 2026-10-06, disclosed to the SEC on 2026-10-08.
Scheduled sale ($143k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.03 | 3,375 | $108K | 75.5% |
| 2 | $30.66 | 1,147 | $35K | 24.5% |
| Total | $31.68 avg | 4,522 | $143K | 100% |
| Filing → |
| RAPP | SELL | 2026-10-23 | $64K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $249K | — | Filing → |